Trials / Active Not Recruiting
Active Not RecruitingNCT06192888
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
Pilot Study of Glofitamab and Lenalidomide in Patients With Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With a BTK Inhibitor
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out whether the combination of glofitamab and lenalidomide is an effective treatment for relapsed or refractory Mantle Cell Lymphoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Glofitamab | IV Glofitamab |
| DRUG | Obinutuzumab | IV Obinutuzumab |
| DRUG | Lenalidomide | Oral Lenalidomide |
Timeline
- Start date
- 2024-01-08
- Primary completion
- 2028-01-08
- Completion
- 2028-01-08
- First posted
- 2024-01-05
- Last updated
- 2026-03-27
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06192888. Inclusion in this directory is not an endorsement.